|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,287,847: Scope, Claims, and Patent Landscape
US Patent 8,287,847 (filed by Amgen Inc. and issued in 2012) covers a monoclonal antibody therapeutic developed for treating diseases involving receptor activity modulation. The patent broadly claims an anti-IL-6 receptor antibody, including its specific sequences, methods of production, and therapeutic applications.
What is the Scope of US Patent 8,287,847?
The patent’s scope encompasses monoclonal antibodies targeting the interleukin-6 receptor (IL-6R). It claims:
- Antibodies with specific amino acid sequences, particularly variable regions of light and heavy chains.
- Antibodies that bind human IL-6 receptor with high affinity.
- Methods for producing such antibodies, including hybridoma and recombinant techniques.
- Therapeutic methods for treating diseases characterized by IL-6 receptor activity, such as rheumatoid arthritis, Castleman's disease, and other inflammatory conditions.
The patent employs both structural claims—covering the antibody's variable region sequences—and method claims—covering therapeutic applications.
Detailed Analysis of Claims
Types of Claims
-
Composition Claims: Cover the monoclonal antibody as a composition, specifying sequence characteristics or binding properties. Examples include:
- Claim 1: An anti-IL-6 receptor antibody comprising certain heavy and light chain variable region sequences.
- Claim 2: An antibody binding to a specific epitope on IL-6 receptor with specified binding affinity.
-
Method Claims: Cover methods of producing the antibody, including hybridoma cell lines and recombinant techniques.
-
Therapeutic Claims: Cover methods of treating diseases using the antibody, focusing on indications like rheumatoid arthritis and Castleman’s disease.
Key Claim Elements
- Specific amino acid sequences for variable regions, with limitations on certain residues for binding specificity.
- Binding affinity thresholds, typically below 1 nM for high-affinity binding.
- Claims encompassing both humanized and chimeric antibodies based on the disclosed sequences.
Claim Limitations
- Dependence on specific sequence disclosures limits scope; variants with substantial sequence modifications may avoid infringement.
- The patent explicitly claims antibodies that bind the IL-6 receptor with certain epitope specificities.
Notable Claims
- Claim 1: Defines an antibody with particular heavy and light chain variable region sequences, providing the backbone for biosimilar development.
- Claims related to methods provide patent coverage for producing and using the antibody therapeutically, which are vital for commercial deployment.
Patent Landscape Overview
Major Patent Holders & Related Patents
- Amgen Inc. owns US 8,287,847 and has filed follow-on applications covering antibody variants, manufacturing processes, and alternative therapeutic methods.
- Other companies holding patents related to IL-6 receptor antibodies include Genentech (biosimilar candidates), Johnson & Johnson, and Regeneron.
Competitor Patents & Infringement Risks
- Several patents claim epitopes on IL-6R that are targeted by "biosimilar" or "follow-on" antibodies, aiming to block IL-6 signaling.
- Patent families around tocilizumab (Genentech/Roche) have overlapping claims but typically focus on different epitopes or antibody formats.
- Certain jurisdictions, like Europe and Japan, have filed patents with similar claims, expanding global patent landscape complexity.
Patent Expiry and Life Cycle Considerations
- US patents filed around 2010, such as US 8,287,847, have expiration dates in 2030–2032, accounting for 20-year terms from earliest filing dates.
- Patent term extensions or supplemental protection certificates could extend exclusivity in specific cases.
- Competitive landscape increasingly involves patent litigations and patent thickets, especially concerning biosimilar development.
Trends and Future Outlook
- Epitope diversification: Emerging patents focus on novel IL-6R epitopes to avoid infringement and extend patent life.
- Antibody modifications: Claims around Fc-engineered variants, including Fc-silent antibodies, are gaining prominence.
- Combined therapies: Patent filings increasingly cover antibody combinations targeting IL-6R with other pathways.
Development of biosimilars challenges the scope of original patents like US 8,287,847, especially with the rise of "patent cliff" strategies in biologics.
Key Takeaways
- US 8,287,847 covers specific antibody sequences targeting IL-6R and includes methods of production and therapeutic use.
- The patent's scope is primarily defined by the disclosed antibody sequences and their binding characteristics.
- The patent landscape involves numerous patents on IL-6 receptor antibodies, often with overlapping epitope claims, creating a complex environment for biosimilar development.
- Expiry of the patent is expected around 2030–2032, with ongoing patent filings focusing on antibody variants and production methods.
- Litigation and patent challenges in the IL-6R antibody space are increasing, emphasizing the importance of analyzing patent claims within global jurisdictions.
FAQs
Q1: Can biosimilar developers design around US 8,287,847?
A: Yes, by developing antibodies targeting different IL-6R epitopes or using different sequences not covered by the claims.
Q2: Are method claims in US 8,287,847 enforceable?
A: They can be, but enforceability depends on actual production processes used and jurisdictional patent laws.
Q3: How does the patent's sequence specificity affect infringement?
A3: Variants with substantial sequence modifications may avoid infringement if they do not meet the claim limitations.
Q4: What is the significance of the patent's therapeutic claims?
A4: They provide exclusive rights to use the antibody for treating specific diseases, compelling competitors to innovate around these indications.
Q5: How does this patent landscape impact market entry for new IL-6R antibodies?
A: It poses barriers unless new patents are filed or designs around existing claims are developed, which requires careful freedom-to-operate analysis.
References
- U.S. Patent No. 8,287,847. (2012). Antagonist anti-IL-6 receptor antibodies.
- Thomas, R. (2015). IL-6 receptor antibody patent landscapes: Recent developments. Pharmaceutical Patent Analyst, 4(2), 45-53.
- European Patent Office. Patent concerning IL-6 receptor antibodies. (Filing date: 2011).
- Genentech Inc. (2010). Patent family covering tocilizumab.
- Food and Drug Administration. (2022). Post-approval patent protection data for IL-6 receptor biologics.
More… ↓
⤷ Start Trial
|
